The SP1-SuperEnhancer-SPHK1 Axis Mediates Niraparib Resistance in TNBC

<b>Background</b>: PARP inhibitors exhibit significant lethality in tumors with BRCA1/2 mutations or homologous recombination defects; however, their clinical application is limited by the rarity of BRCA1/2 mutations, complex resistance mechanisms, and limited efficacy of monotherapy. <b>Objective</...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Yu-Xia Yuan, Rui-Jia Chen, Gui-Hui Tu, Chao-Qi Li, Long-Long Xu, Yi-Ling Lu, Li-Xian Wu
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2025-10-01
Цуврал:	Pharmaceuticals
Нөхцлүүд:	niraparib sphingolipid metabolism SPHK1 super-enhancers SP1
Онлайн хандалт:	https://www.mdpi.com/1424-8247/18/11/1622
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!